My high-tech aversion caused me to make fun of the typical biotech enterprise: $100 million in cash from selling shares, one hundred Ph.D.’s, 99 microscopes, and zero revenues.
My high-tech aversion caused me to make fun of the typical biotech
My high-tech aversion caused me to make fun of the typical biotech enterprise: $100 million in cash from selling shares, one hundred Ph.D.’s, 99 microscopes, and zero revenues.
